Special Issue "Cellular Stress in Cancer Progression, Drug Resistance and Treatment"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 November 2018).
Interests: signal transduction in cancer; tumour-immune interactions; the mechanisms of resistance to small molecules; monoclonal antibody (mAb)-targeted therapies in cancer; the impact of somatic mutations on targeted therapy responses; immune-modulatory therapies and stress-related cell signaling pathways
Interests: death receptors; apoptosis; cell death signalling; leukemia; leukemic stem cells; tumour-microenvironment interaction; drug resistance
Cellular stress is an inherent feature of carcinogenesis, from the start of malignant transformation throughout tumour progression to drug resistance. The normal cell stress response engages a number of checkpoints that can: 1) arrest the cell cycle temporarily to allow repair; 2) permanently arrest the cell cycle (senescence); or 3) initiate cell death. Correct functioning of these responses is essential for tumour suppression, meaning they are often aberrant in cancer.
Cellular stress pathways are triggered in malignant cells both by inherent processes in the malignant cells, such as oncogenic stress, insufficient nutrient and oxygen supply, DNA damage and endoplasmic reticulum stress due to, for example, accumulating mutant proteins as well as by extrinsic factors, such as chemotherapeutics. The cellular stress response of the tumour cells can also impact on the tumour microenvironment, including the residing the immune response against the tumour and inflammation, an area that is now at the forefront in anti-cancer therapeutic strategies.
The importance of these cell stress pathways in cancer is increasingly recognized in recent research, both as a driver of carcinogenesis and as a target for therapy. The aim of this Special Issue is to provide an updated overview of the current progress in the field and highlight perspectives and challenges for the future and invites contributions from all areas related to cellular stress pathways in cancer development, how they impact on drug resistance and may be exploited for therapy.
Dr. Denis Collins
Dr. Eva Szegezdi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.